○ The solution will accept output from a wide range of ophthalmic devices and input formats, and convert to standard DICOM formats (e.g. using freeware tools).
  ● Usability and interface for image viewing
○ The solution will have an easy-to-use interface for clinicians with a range of experience and comfort level with technology.
○ The solution will provide the ability to view and annotate diagnostic-quality ophthalmic images.
  ● Integration with workflow
○ The solution will be convenient to integrate into clinical ophthalmology workflow, to install on existing office hardware platforms, and to integrate with existing EHR systems (e.g. “single sign-on”).
  ● Platform Neutrality

Additional Information
Ownership of intellectual property is determined by the following:
  ● Each entrant retains title and full ownership in and to their submission. Entrants expressly reserve all intellectual property rights not expressly granted under the challenge agreement.
  ● By participating in the challenge, each entrant hereby irrevocably grants to Sponsor and Administrator a limited, non-exclusive, royalty free, worldwide, license and right to reproduce, publicly perform, publically display, and use the Submission to the extent necessary to administer the challenge, and to publically perform and publically display the Submission, including, without limitation, for advertising and promotional purposes relating to the challenge.

Farzad Mostashari,
National Coordinator for Health Information Technology.[FR Doc. 2012–11591 Filed 5–11–12; 8:45 am]
BILLING CODE 4150–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Alcohol-related Motor Vehicle Injury Research, FOA CE12–006, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

TIME AND DATE: 12 p.m.–2:30 p.m., June 12, 2012 (Closed).

PLACE: Teleconference.

STATUS: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

MATTERS TO BE DISCUSSED: The meeting will include the initial review, discussion, and evaluation of applications received in response to “Alcohol-related Motor Vehicle Injury Research, FOA CE12–006, initial review.”

CONTACT PERSON FOR MORE INFORMATION:
Jane Suen, Dr.P.H., M.S., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F63, Atlanta, Georgia 30341–3724, Telephone (770) 488–4281.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2012–11546 Filed 5–11–12; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Healthcare Infection Control Practices Advisory Committee (HICPAC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee:

TIMES AND DATES: 9:00 a.m.–5:00 p.m., June 14, 2012.
9:00 a.m.–12:00 p.m., June 15, 2012.

PLACE: CDC, Global Communications Center, Building 19, Auditorium B3, 1600 Clifton Road NE., Atlanta, Georgia, 30333

STATUS: Open to the public, limited only by the space available. Please register for the meeting at www.cdc.gov/hicpac.

PURPOSE: The Committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health and Human Services, the Director, CDC, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), and the Director, Division of Healthcare Quality Promotion regarding 1) the practice of healthcare infection control; 2) strategies for surveillance, prevention, and control of infections (e.g., nosocomial infections), antimicrobial resistance, and related events in settings where healthcare is provided; and 3) periodic updating of guidelines and other policy statements regarding prevention of healthcare-associated infections (HAIs) and healthcare-related conditions.

MATTERS TO BE DISCUSSED: The agenda will include updates on CDC’s activities for HAIs including outbreaks and guidance on the use of single-dose vials; draft guideline for prevention of infections among patients in neonatal intensive care units (NICU); draft guideline for management of occupational exposures to HIV and recommendations for post-exposure prophylaxis; draft guidance for facility adjudication of infection data; and an update on National Healthcare Safety Network (NHSN) validation and surveillance definitions for central-line associated bloodstream infections and surgical site infections. Time will be available for public comment.

Agenda items are subject to change as priorities dictate.

CONTACT PERSON FOR MORE INFORMATION:
Erin Stone, M.S., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton Road NE., Mailstop A–07, Atlanta, Georgia, 30333, Telephone (404) 639–4045, Email: hicpac@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2012–11547 Filed 5–11–12; 8:45 am]
BILLING CODE 4163–18–P